PathoBrainSeq Announces Submission of Provisional Patent, Marking a Milestone in Neurodiagnostic Innovation

Pioneering NeuroMap Diagnostics Technology Poised to Transform Neurodegenerative Disease Detection

[2023-12-28]

[Palo Alto] – PathoBrainSeq, an emerging leader in the field of neurodiagnostic solutions, is thrilled to announce the submission of a provisional patent for its groundbreaking NeuroMap Diagnostics technology. This significant step underscores our commitment to advancing the early detection and management of neurodegenerative diseases.

NeuroMap Diagnostics, our flagship product, represents a leap forward in the realm of medical science, utilizing advanced single-cell RNA sequencing and whole-genome analysis. This innovative approach enables precise, non-invasive detection of neurological conditions such as Alzheimer's, Parkinson's, and ALS, directly from a patient's blood sample.

“Our team has worked tirelessly to reach this point,” says Goonho Park, PhD, CEO & founder of PathoBrainSeq. “The submission of this provisional patent is not just a milestone for our company but a beacon of hope for millions affected by neurodegenerative diseases. It brings us one step closer to offering a solution that can significantly improve the quality of life for patients and their families.”

The provisional patent submission is a testament to PathoBrainSeq’s dedication to scientific excellence and innovation. With this development, PathoBrainSeq is poised to make a significant impact in the healthcare industry, offering new avenues for diagnosis and treatment in the field of neurology.

PathoBrainSeq is committed to continuing its research and development efforts. Our goal is to ensure that NeuroMap Diagnostics becomes a standard tool in neurodegenerative disease management, globally recognized for its accuracy, reliability, and ease of use.